Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter，Phase III Clinical Study of Recombinant Anti-PD-L1 Monoclonal Antibody (ZKAB001) for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

NCT04359550 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.

NCT NCT04359550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04359550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter，Phase III Clinical Study of Recombinant Anti-PD-L1 Monoclonal Antibody (ZKAB001) for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy
Lead sponsor
Lee's Pharmaceutical Limited
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2020
Completion date
June 1, 2023
Enrollment
362 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade osteosarcoma